Literature DB >> 16595495

Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management.

Holger Palmedo1, Jan Bucerius, Alexius Joe, Holger Strunk, Niclas Hortling, Susanne Meyka, Roland Roedel, Martin Wolff, Eva Wardelmann, Hans-Juergen Biersack, Ursula Jaeger.   

Abstract

UNLABELLED: The aim of this study was to investigate the diagnostic accuracy and impact on patient management of the new integrated PET/CT modality in patients with suspected iodine-negative, differentiated thyroid carcinoma (DTC).
METHODS: Forty patients with DTC and a suggestion of iodine-negative tumor tissue underwent PET/CT examination (370 MBq (18)F-FDG, coregistered PET/CT whole-body images). As the first step of analysis, PET and CT images were scored blindly and independently by 2 nuclear medicine physicians and 2 radiologists. A 5-point scale was used. The second step consisted of a consensus reading, during which a virtual side-by-side fusion of PET and CT images was initially evaluated and afterward the "real" fusion (i.e., coregistered) PET/CT images were also scored with the same 5-point scale. The imaging results were compared with histopathologic findings and the course of disease during further follow-up examinations.
RESULTS: One hundred twenty-seven lesions in 40 patients were evaluated. Diagnostic accuracy was 93% and 78% for PET/CT and PET, respectively (P = 0.049, per-patient analysis). In 17 (74%) of 23 patients with suspicious (18)F-FDG foci, integrated PET/CT added relevant information to the side-by-side interpretation of PET and CT images by precisely localizing the lesion(s). In tumor-positive PET patients, PET/CT fusion by coregistration led to a change of therapy in 10 (48%) patients. Futile surgery was prevented in an additional 3 patients.
CONCLUSION: Integrated PET/CT is able to improve diagnostic accuracy in a therapeutically relevant way in patients with iodine-negative DTC. By precisely localizing tumor tissue, image fusion by integrated PET/CT is clearly superior to side-by-side interpretation of PET and CT images.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16595495

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

1.  Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.

Authors:  Fabio Pomerri; Anna Rita Cervino; Faise Al Bunni; Laura Evangelista; Pier Carlo Muzzio
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

2.  Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.

Authors:  R J D Prestwich; S Viner; G Gerrard; C N Patel; A F Scarsbrook
Journal:  Br J Radiol       Date:  2012-10       Impact factor: 3.039

3.  Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma.

Authors:  Thomas Borschitz; Waltraud Eichhorn; Christian Fottner; Torsten Hansen; Arno Schad; Simin Schadmand-Fischer; Matthias M Weber; Mathias Schreckenberger; Hauke Lang; Thomas J Musholt
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 4.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

5.  Comparison of diagnostic and prognostic capabilities of ¹⁸F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer.

Authors:  Shigeki Nagamachi; Hideyuki Wakamatsu; Shogo Kiyohara; Ryuichi Nishii; Youichi Mizutani; Seigo Fujita; Shigemi Futami; Hideo Arita; Masaomi Kuroki; Hiroshi Nakada; Noriko Uchino; Shozo Tamura; Keiichi Kawai
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

6.  Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose.

Authors:  O Caleo; S Maurea; M Klain; B Salvatore; G Storto; M Mancini; L Pace; M Salvatore
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

Review 7.  Role and cost effectiveness of PET/CT in management of patients with cancer.

Authors:  Muhammad Wasif Saif; Ifigenia Tzannou; Nektaria Makrilia; Kostas Syrigos
Journal:  Yale J Biol Med       Date:  2010-06

8.  Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Andrea Frilling; Hilmar Kühl; Stefan P Müller; Walter Jentzen; Andreas Bockisch; Gerald Antoch
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

9.  Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic ¹³¹I whole-body scan and detectable serum thyroglobulin levels.

Authors:  Laura Agate; Francesca Bianchi; A Giorgetti; P Sbragia; V Bottici; F Brozzi; P Santini; E Molinaro; P Vitti; R Elisei; C Ceccarelli
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

10.  Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.

Authors:  Joaquim Bosch-Barrera; Leire Arbea; Maria J García-Velloso; Ignacio Gil-Bazo; Jesús García-Foncillas; Carlos Panizo
Journal:  Cases J       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.